Amphastar P Cash Flow Conversion Efficiency
Amphastar P cash flow conversion efficiency. Based on the latest financial reports, Amphastar P (AMPH) has a cash flow conversion efficiency ratio of 0.067x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($51.32 Million) by net assets ($768.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Amphastar P (2012–2025)
Cash flow conversion efficiency of Amphastar P from 2012 to 2025. This chart illustrates how Amphastar P's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Amphastar P for real-time trading data and today's change.
Amphastar P Cash Flow Conversion Ratio Explained
Amphastar P cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Amphastar P Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amphastar P ranked by their cash flow conversion efficiency. Also see AMPH company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zimplats Holdings Ltd
AU:ZIM
|
-0.001x |
|
Zhuzhou Huarui Precision Cutting Tools Co Ltd
SHG:688059
|
0.039x |
|
Leedarson IoT Technology Inc
SHG:605365
|
-0.025x |
|
Marten Transport Ltd
NASDAQ:MRTN
|
0.036x |
|
Kingfa Science & Technology (India) Limited
NSE:KINGFA
|
0.078x |
|
Tanac Automation Co Ltd
SHE:300461
|
-0.051x |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
0.024x |
|
Hexatronic Group AB
ST:HTRO
|
0.008x |
Annual Cash Flow Conversion Efficiency for Amphastar P (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amphastar P from 2012 to 2025. Review AMPH cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $788.80 Million | $156.12 Million | 0.198x | -32.08% |
| 2024-12-31 | $732.30 Million | $213.39 Million | 0.291x | +1.54% |
| 2023-12-31 | $639.42 Million | $183.50 Million | 0.287x | +70.12% |
| 2022-12-31 | $528.66 Million | $89.18 Million | 0.169x | -23.30% |
| 2021-12-31 | $445.52 Million | $97.99 Million | 0.220x | +72.35% |
| 2020-12-31 | $448.72 Million | $57.27 Million | 0.128x | +30.65% |
| 2019-12-31 | $427.53 Million | $41.76 Million | 0.098x | -6.81% |
| 2018-12-31 | $364.36 Million | $38.19 Million | 0.105x | -9.82% |
| 2017-12-31 | $337.33 Million | $39.21 Million | 0.116x | -0.75% |
| 2016-12-31 | $329.25 Million | $38.56 Million | 0.117x | +224.01% |
| 2015-12-31 | $295.51 Million | $10.68 Million | 0.036x | -51.61% |
| 2014-12-31 | $281.86 Million | $21.05 Million | 0.075x | -39.48% |
| 2013-12-31 | $251.54 Million | $31.04 Million | 0.123x | +1845.92% |
| 2012-12-31 | $233.44 Million | $-1.65 Million | -0.007x | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more